Regeneron Pharmaceuticals (REGN) has been on my watchlist for a while. I looked at the shares in September when shares were trading at $430 and updated my cautious thesis when the company released its third-quarter results. At the time, shares traded just above the $400 mark, as I was not tempted to buy those levels yet.
By now shares have fallen back to $330 per share after the company reported its annual results, as the continued growth of the business and decline in the share price warrant another update of the prospects for Regeneron.
In previous analyses, I feared the reliance on EYLEA amidst a 30-32 times earnings multiple (back in September) even as Regeneron was stepping up its diversification efforts. As multiples have come down a great deal and diversification results are starting to show up, I am a buyer of dips to the $300 mark.

